Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSPO Occupancy in the Human Lung
NCT07362290Enrolling by invitation
- Sponsor
- Imperial College London
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of emapunil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Imperial College London. Primary endpoint: Relationship between plasma concentration of XBD173 and TSPO occupancy in the human lung up to 4 months. Started Sep 2025; status: enrolling by invitation.
02
Drugs
emapunil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07362290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362290.